Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement PIPE Financing On July 28, 2026, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (the “ PIPE Investor ”), pursuant to which the Company agreed to issue and sell to the PIPE Investor an aggregate of 37,812 shares of Series F convertible preferred stock, par value $0.00001 per share (“ Series F Preferred Stock ”), for an aggregate…

Director — Andrew Oakley and Thomas Meier: Mr. Oakley and Mr. Meier resigned from their positions as Directors, with no disagreement noted.

Chief Executive Officer — David White: David White was appointed as the Chief Executive Officer of Onconetix, Inc.

Chief Executive Officer — David White: David White was appointed as the Chief Executive Officer of Onconetix, Inc.

Other Events Press Release On February 12, 2026, Onconetix issued a press release announcing the entry into the Share Exchange Agreement (the “ Press Release ”). The Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Business of Realbotix Realbotix is a technology company focused on designing and manufacturing artificial intelligence (“ AI ”) powered humanoid robots built for meaningful human interaction such as customer service, hospitality and healthcare.…

Entry into a Material Definitive Agreement. This section describes the material provisions of the Share Exchange Agreement (as defined below) but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of the Share Exchange Agreement, a copy of which is attached hereto as Exhibit 2.1. Unless otherwise defined herein, the capitalized terms used below are defined in the Share Exchange Agreement. Share Exchange A…

The filing details compensation adjustments for an interim executive, not a management change.

Entry Into a Material Definitive Agreement On December 6, 2025, Proteomedix AG, a Swiss Company (“Proteomedix”), a wholly-owned subsiairy of Onconetix, Inc. (the “Company”), entered into an amendment (the “Amendment”) of the license agreement with Laboratory Corporation of America Holdings (“Labcorp”) dated as of March 27, 2023, by and between the Company and Labcorp (the “Agreement”), pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products…

Unregistered Sales of Equity Securities. The information provided in

Entry into a Material Definitive Agreement. PIPE Financing On October 1, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (“ Series E Preferred Stock ”), which are convertible into common stock of the Compa…

shall have the meanings ascribed to such terms in the Merger Agreement. On September 5, 2025, Ocuvex received written notice from the Company that the Company had received a Parent Acquisition Proposal and determined that such Parent Acquisition Proposal is a Parent Superior Proposal. On September 5, 2025, the Board of Directors of the Company made a Parent Adverse Recommendation Change. Effective September 24, 2025, pursuant to Section 9.01(a) of the Merger Agreement, the Parties entered int…

Unregistered Sales of Equity Securities. The information provided in

Entry into a Material Definitive Agreement. PIPE Financing On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock o…

Entry Into a Material Definitive Agreement On September 17, 2025, Proteomedix AG (“ Proteomedix ”), a wholly-owned subsidiary of Onconetix, Inc. (the “ Company ”), entered into a licensing agreement (the “ Agreement ”) with Immunovia, Inc. (“ Immunovia ”), a pancreatic cancer diagnostics company based in Lund, Sweden. Under the Agreement, Proteomedix will provide Immunovia with master cell lines required to produce antibodies for three of the five biomarkers used in the PancreaSure test, as w…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in

Entry Into a Material Definitive Agreement Keystone Capital LLC Promissory Note and KCP Fund I Promissory Note On August 28, 2025, Onconetix, Inc. (the “ Company ”) issued promissory note to each of (i) Keystone Capital Partners, LLC (“ Keystone ” and such note, the “ Keystone Note ”) and (ii) KCP Fund I, LLC, an affiliate of Keystone (the “ KCP Note ”, and together with the Keystone Note, the “ Notes ”) each with original issue discount of $8,823.53 and a principal amount of $58,823.53. The…

Director — Ajit Singh: Ajit Singh resigned as a member of the Board of Directors.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in

Entry Into a Material Definitive Agreement Keystone Capital LLC Promissory Note On August 6, 2025, Onconetix, Inc. (the “ Company ”) issued a promissory note (the “ Keystone Note” ) to Keystone Capital Partners, LLC (“ Keystone ”) with original issue discount of $17,647.06, in an aggregate principal amount of $117,647.06. The note is due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from its equity line of credit with Keystone (the “ ELOC ”) and (ii) March 6…

Lead Independent Director — Andrew Oakley: Andrew Oakley was elected as Lead Independent Director, expanding his role within the company.

Entry into a Material Definitive Agreement. General Description of the Agreement and Plan of Merger On July 16, 2025, Onconetix, Inc, a Delaware corporation (“ Onconetix ” or “ Parent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among (i) Parent, (ii) Onconetix Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“ Merger Sub ”), (iii) Ocuvex Therapeutics, Inc., a Delaware corporation (“ Ocuvex ” or the “ Company ”) a…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in

Entry Into a Material Definitive Agreement On June 5, 2025, Onconetix, Inc. (the “ Company ”) issued a promissory note to Keystone Capital Partners, LLC with original issue discount of $22,058.82, in an aggregate principal amount of $147,058.82. The note is due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from the ELOC and (ii) March 5, 2026, subject to mandatory prepayment in the event that the Company raises sufficient additional capital through other sec…

of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in